Trial NCT03382574

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

This randomized pilot clinical trial studies how well denosumab works in BRCA1/2 mutations carriers scheduled for risk-reducing salpingo-oophorectomy. Immunotherapy with denosumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.


Denosumab, Salpingo-Oophorectomy


BRCA1 Gene Mutation, BRCA2 Gene Mutation, Premenopausal


Judy E. Garber, Kevin Holcomb, Powel H. Brown, Nadir Arber, Meghna S. Trivedi, Robert M. Wenham, Eitan Friedman

See list of participating sites